Pyrazole Boronic Acid Composition for Selective Proteasome Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current proteasome inhibitors suffer from poor biological selectivity, stability, solid tumor inhibition, and significant toxic and side effects, limiting their clinical application.
Innovation Solution
Development of a pyrazole boronic acid compound represented by formula I, its pharmaceutically acceptable salts, or stereoisomers, which can be formulated into pharmaceutical compositions for use as proteasome inhibitors to treat proteasome-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing proteasome inhibitors are used, then proteasome inhibition effect is achieved, but biological selectivity is poor and toxic side effects are significant
Solution Approach 1:
The patent modifies the molecular structure of proteasome inhibitors by changing chemical parameters - specifically incorporating pyrazole boronic acid compounds with specific substituents (R1-R6 groups) to improve biological selectivity and reduce toxic side effects while maintaining proteasome inhibition activity
Solution Approach 2:
The invention uses composite molecular structures combining pyrazole boronic acid core with various substituent groups (aromatic rings, heterocycles, alkyl chains) to create molecules that achieve both high selectivity and reduced toxicity through synergistic effects of different structural components
2Reliability
If existing proteasome inhibitors are used, then proteasome inhibition is achieved, but stability in vivo and in vitro is poor
Solution Approach 1:
The patent enhances molecular stability by modifying chemical parameters - introducing specific substituent patterns (R1-R6) on the pyrazole boronic acid core that improve metabolic stability and resistance to degradation, thereby extending the duration of action in biological systems
3Reliability
If existing proteasome inhibitors are used, then proteasome inhibition is achieved, but solid tumor inhibition effect is poor
Solution Approach 1:
The invention optimizes tumor penetration and inhibition efficacy by adjusting molecular parameters - specifically using pyrazole boronic acid compounds with appropriate lipophilicity and molecular size (defined by R1-R6 substituents) to improve delivery to solid tumors and enhance inhibition effect in this difficult-to-treat cancer type
Data Source
AI summary
The present application relates to a pyrazole boronic acid compound represented by the following formula I, pharmaceutically acceptable salts or stereoisomers thereof, a pharmaceutical composition containing same, and uses thereof. The compound, the pharmaceutically acceptable salts or stereoisomers thereof and the pharmaceutical composition containing same can be used for preparing proteasome inhibitors.